Colchicine drug-to-drug interactions
The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.
1. A method of treating a colchicine sensitive disorder, comprising orally co-administering a liquid colchicine solution and a CYP3A4 inhibitor to a human subject having a colchicine sensitive disorder in an effective amount to treat the disorder, wherein the liquid colchicine solution comprises a concentration of colchicine of 0.01-1.0 mg/ml, 0.1-0.3% w/v of anhydrous citric acid, 0.8-1.6% w/v of dibasic sodium phosphate heptahydrate, 0.1-0.2% w/v of a thickening agent, a preservative, and water.
2. The method of claim 1 , wherein the CYP3A4 inhibitor is a strong CYP3A4 inhibitor.
3. The method of claim 1 , wherein the strong CYP3A4 inhibitor is posaconazole.
4. The method of claim 3 , wherein the dose of posaconazole is 300-600 mg/dose/day.
5. The method of claim 3 , wherein the dose of the liquid colchicine solution is reduced to 2.5 mL or lower once or twice a day when coadministered with posaconazole.
6. The method of claim 3 , wherein there is a 2-6 fold increase in colchicine blood levels when posaconazole is co-administered with liquid colchicine solution.
7. The method of claim 1 , wherein the CYP3A4 inhibitor is a weak CYP3A4 inhibitor.
8. The method of claim 7 , wherein weak CYP3A4 inhibitor is amlodipine besylate.
9. The method of claim 8 , wherein the dose of amlodipine besylate is 5-10 mg/dose/day.
10. The method of claim 8 , wherein there is no significant effect on colchicine blood levels when liquid colchicine solution is taken in conjunction with amlodipine besylate.
11. The method of claim 1 , wherein the CYP3A4 inhibitor is a moderate CYP3A4 inhibitor.
12. The method of claim 11 , wherein moderate CYP3A4 inhibitor is ciprofloxacin hydrochloride.
13. The method of claim 12 wherein the dose of ciprofloxacin hydrochloride is 20-750 mg/dose/day.
14. The method of claim 12 , wherein there is no significant effect on colchicine blood levels when liquid colchicine solution is taken in conjunction with ciprofloxacin hydrochloride.
15. The method of claim 1 , wherein the dose of colchicine is 0.5-1.2 mg/dose/day.